We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (ANGEL-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03239860
Recruitment Status : Terminated (Based on R&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1.)
First Posted : August 4, 2017
Last Update Posted : October 20, 2020
Les Laboratoires Servier
Worldwide Clinical Trials
Institut de Recherches Internationales Servier
Information provided by (Responsible Party):
GeNeuro SA